SEHK:2269Life Sciences
Assessing WuXi Biologics (SEHK:2269) Valuation After New Autoimmune And Biologics Collaboration Wins
WuXi Biologics (Cayman) (SEHK:2269) has drawn fresh attention after entering into a license and research service agreement with Vertex Pharmaceuticals for trispecific T cell engagers targeting B cell mediated autoimmune diseases.
See our latest analysis for WuXi Biologics (Cayman).
Those fresh collaborations with Vertex, Sinorda and HanchorBio arrive as WuXi Biologics’ share price sits at HK$36.98, with a 1 month share price return of 13.64% and a 1 year total shareholder return of 87.91%...